Accreditation Information

Boston University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Boston University School of Medicine designates this live activity for a maximum of 10.75 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.75 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program.
The Continuing Nursing Education Provider Unit, Boston University School of Medicine is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.

AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credits™ from organizations accredited by ACCME or a recognized state medical society. Physician assistants may receive a maximum of 11.25 hours of Category I credit for completing this program.

The program has been submitted to ABCGN for GI-specific approval.


Needs Statement

An estimated 1.6 million individuals currently have IBD in the US. Another more recent study suggests that this number may be as high as 3.1 million. A 2004 National Institute of Health (NIH) report revealed that there were 1.1 million ambulatory care visits for CD, 1.8 million prescriptions, and in 2013 CD patients had 196,480 hospitalizations. There were 716,000 ambulatory care visits and 2.1 million prescriptions for UC treatment, and 107,000 hospitalizations for patients with UC in 2010.

The goal of the conference is to initiate practice changes in GI practices in the diagnosis and management of patients with CD and UC so as to improve quality of life for these patients while prolonging clinical remission. This meeting will provide support and enable participating clinicians to enhance their knowledge, competency and performance in the areas of patient care, medical knowledge, and practice-based learning and improvement.  It will address the need for education on selecting treatment for IBD patients who are unable to achieve remission and as well as discuss the newer agents and those that may soon be available for the treatment of IBD.



At the conclusion of this activity, participants will be able to (or better able to):

  1. Determine the benefits and risks of biologic treatments in patients with inflammatory bowel disease.
  2. Evaluate the role of diet in the control of inflammatory bowel disease, and understand how diet affects microbiota.
  3. Review the role of diagnostic imaging and endoscopic biopsy in the diagnosis and monitoring of Crohn disease and UC.
  4. Identify the most current approaches to the management of postoperative recurrence in Crohn’s disease.
  5. Describe the medical and surgical approaches in patients with severe ulcerative colitis and pouchitis.
  6. Recognize the benefits of health maintenance (immunizations, psychosocial screening, and skeletal health assessment) in patients with Crohn’s disease and ulcerative colitis.
  7. Recognize how to effectively advocate for your patient when third party payors or specialty pharmacies deny care or access to needed treatments.


Target Audience

This course is designed for practicing gastroenterologists, pediatric gastroenterologists, colorectal surgeons, nurses and other healthcare professionals caring for patients with Crohn’s disease and ulcerative colitis.


Faculty Disclosure

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.